Tango Therapeutics Stock Forecast, Price & News

Tango Therapeutics (NASDAQ:TNGX) Frequently Asked Questions

Is Tango Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tango Therapeutics stock.
View analyst ratings for Tango Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Tango Therapeutics?

Wall Street analysts have given Tango Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tango Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tango Therapeutics?

Tango Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 324,300 shares, an increase of 592.9% from the August 31st total of 46,800 shares. Based on an average trading volume of 167,400 shares, the short-interest ratio is currently 1.9 days. Approximately 0.9% of the shares of the stock are short sold.
View Tango Therapeutics' Short Interest.

What price target have analysts set for TNGX?

4 brokers have issued twelve-month price objectives for Tango Therapeutics' stock. Their forecasts range from $16.00 to $17.00. On average, they anticipate Tango Therapeutics' stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 17.6% from the stock's current price.
View analysts' price targets for Tango Therapeutics or view top-rated stocks among Wall Street analysts.

Who are some of Tango Therapeutics' key competitors?

Some companies that are related to Tango Therapeutics include TG Therapeutics (TGTX), Mawson Infrastructure Group (WIZP), Arvinas (ARVN), Schrödinger (SDGR), Arena Pharmaceuticals (ARNA), 23andMe (ME), Karuna Therapeutics (KRTX), Reata Pharmaceuticals (RETA), Galapagos (GLPG), Hypera (HYPMY), Zentalis Pharmaceuticals (ZNTL), Atea Pharmaceuticals (AVIR), Cryoport (CYRX), Intra-Cellular Therapies (ITCI) and Nektar Therapeutics (NKTR).
View all of TNGX's competitors.

What is Tango Therapeutics' stock symbol?

Tango Therapeutics trades on the NASDAQ under the ticker symbol "TNGX."

How do I buy shares of Tango Therapeutics?

Shares of TNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tango Therapeutics' stock price today?

One share of TNGX stock can currently be purchased for approximately $14.03.

How much money does Tango Therapeutics make?

Tango Therapeutics has a market capitalization of $1.23 billion.

How many employees does Tango Therapeutics have?

Tango Therapeutics employs 4 workers across the globe.

Where are Tango Therapeutics' headquarters?

Tango Therapeutics is headquartered at 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.